US primary research · Flu/COVID-19 COMBO · Adults 50+

A single flu-COVID shot. Will older Americans take it?

What a US survey of 500+ adults aged 50+ reveals about acceptance, the real decision drivers, and the price ceiling for combination vaccines.

VacZine Analytics US consumer survey, May 2024 (754 initiated, 541 completed; ±4% margin of error, adults 50+). Sample from MarketVIEW: Seasonal influenza vaccines (CAT VAMV036).

64%
likely to accept
a flu–COVID combo
38%
already had flu + COVID
at the same visit
60%
unaware single-shot
combos are in development
500+
US adults 50+ surveyed
±4% margin of error
Latest · 2026

Two years on, the survey’s #1 acceptance driver is materialising. Respondents said regulatory approval and a recommendation mattered most — and that pathway is now opening. Moderna’s flu–COVID combination mCOMBRIAX (mRNA-1083) won European Commission marketing authorisation on 22 April 2026 for adults 50+, the first single vaccine approved against both diseases. Separately, its standalone mRNA flu vaccine mRNA-1010 (mFLUSIVA) cleared the US FDA’s VRBPAC 9–0 on 18 June 2026, with a PDUFA decision due 5 August 2026. The combination route is opening first in the EU. Source: CIDRAP →

Finding 01 — Latent demand

A third already double up. Most would accept the single shot.

When asked about a new influenza–COVID-19 combination vaccine, ~64% of respondents said they were ‘likely to accept’ it. And the behaviour is already in place: ~38% received their flu and COVID-19 vaccines on the same day/visit in 2023–24 — closely consistent with real-world co-administration in England (~35%) and US Medicare beneficiaries (36.5% in the later period). A single-shot combination largely formalises what a third of the 50+ population already does.

One reveal ~64% were ‘likely to accept’ — yet ~60% had no idea a single-shot flu–COVID combo was even in development. The demand is latent, not informed.
Finding 02 — Decision drivers

Recommendation beats convenience - and platform barely registers.

Asked to rank what would influence their choice (1 = most important, 5 = least), respondents were unambiguous: a regulatory approval plus an HCP recommendation (which we assume follows US ACIP) topped the list. Cutting the number of injections did not move them — the 50+ cohort already receives multiple doses. And despite mass exposure to COVID-19 mRNA vaccines, the mRNA platform itself ranked least important of all.

01
Approval + HCP rec
avg 2.7
—
Fewer injections
not a driver
Last
mRNA platform
avg 4.3
One reveal The mRNA-vs-protein debate matters far less to 50+ consumers than the ACIP / HCP recommendation. Win the recommendation and the platform argument largely takes care of itself.
Finding 03 — The friction points

Acceptance has conditions: price, side-effects, and what's in the mix.

Willingness is real but conditional. Three constraints shape how that demand converts — and the first is commercial, not clinical.

Price premium
Clear resistance
General resistance to a COMBO priced above the sum of its components. Premium pricing is the single biggest commercial constraint on uptake.
Reactogenicity
Trade-off accepted
Mostly ambivalent to potentially higher reactogenicity, with a trend to accepting it as a fair trade-off for fewer injections.
RSV / triple
Neutral to warm
Neutral on adding an RSV antigen, but a trend toward favouring its inclusion in a future flu/COVID/RSV ‘triple’ combination.
One reveal Respondents were confident they still understood the need for monovalent COVID-19 doses outside the winter season — a combination shot does not, in their minds, replace off-season boosting.
MarketVIEW · Seasonal influenza vaccines · CAT VAMV036

The full survey - and the global flu forecast

These findings are a sample. The complete 12-question survey, demographic cuts and the global seasonal influenza value & volume forecast to 2040 — including COMBO and mRNA scenarios — sit inside the live MarketVIEW model. Excel forecast + executive presentation, updated for 2026.

View the seasonal influenza report ← Back to homepage